Aytu BioPharma Inc
Company Profile
Business description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Contact
7900 East Union Avenue
Suite 920
DenverCO80237
USAT: +1 720 437-6580
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
83
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
stocks
New production imminent for undervalued ASX gas play
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,324.60 | 40.80 | 0.44% |
CAC 40 | 8,170.82 | 17.77 | -0.22% |
DAX 40 | 24,137.44 | 306.45 | 1.29% |
Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
FTSE 100 | 9,389.34 | 34.77 | 0.37% |
HKSE | 25,858.83 | 611.73 | 2.42% |
NASDAQ | 22,679.97 | 117.44 | 0.52% |
Nikkei 225 | 49,185.50 | 1,603.35 | 3.37% |
NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
S&P 500 | 6,664.01 | 34.94 | 0.53% |
S&P/ASX 200 | 9,031.90 | 43.70 | 0.49% |
SSE Composite Index | 3,863.89 | 24.14 | 0.63% |